Akebia Therapeutics Inc (NASDAQ: AKBA) on Monday, soared 6.86% from the previous trading day, before settling in for the closing price of $1.75. Within the past 52 weeks, AKBA’s price has moved between $0.80 and $2.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -8.86% over the last five years. The company achieved an average annual earnings per share of -1.19%. With a float of $207.61 million, this company’s outstanding shares have now reached $211.54 million.
The firm has a total of 167 workers. Let’s measure their productivity. In terms of profitability, gross margin is 63.13%, operating margin of -20.45%, and the pretax margin is -27.07%.
Akebia Therapeutics Inc (AKBA) Insider Activity
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Akebia Therapeutics Inc is 4.85%, while institutional ownership is 24.86%. The most recent insider transaction that took place on May 13 ’24, was worth 15,140. In this transaction SVP, Chief Legal Officer of this company sold 12,016 shares at a rate of $1.26, taking the stock ownership to the 651,243 shares. Before that another transaction happened on May 13 ’24, when Company’s SVP, Chief Operating Officer sold 34,840 for $1.26, making the entire transaction worth $43,898. This insider now owns 672,092 shares in total.
Akebia Therapeutics Inc (AKBA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.19% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Akebia Therapeutics Inc (AKBA) is currently performing well based on its current performance indicators. A quick ratio of 1.21 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.25 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Analysing the last 5-days average volume posted by the [Akebia Therapeutics Inc, AKBA], we can find that recorded value of 2.32 million was better than the volume posted last year of 2.2 million. As of the previous 9 days, the stock’s Stochastic %D was 24.30%. Additionally, its Average True Range was 0.09.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 67.74%, which indicates a significant increase from 59.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.71% in the past 14 days, which was lower than the 55.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8911, while its 200-day Moving Average is $1.4573. Now, the first resistance to watch is $1.9917. This is followed by the second major resistance level at $2.1133. The third major resistance level sits at $2.2517. If the price goes on to break the first support level at $1.7317, it is likely to go to the next support level at $1.5933. Should the price break the second support level, the third support level stands at $1.4717.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
Market capitalization of the company is 408.00 million based on 218,181K outstanding shares. Right now, sales total 194,620 K and income totals -51,930 K. The company made 37,430 K in profit during its latest quarter, and -20,040 K in sales during its previous quarter.
